Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bramitob vs TOBI in Cystic Fibrosis
NCT00885365Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Apr 2009
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of tobramycin in cystic fibrosis (CF) and Pseudomonas aeruginosa infection (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Change From Baseline to End of the Treatment Period of Forced Expiratory Volume in 1 Second (FEV1), Expressed as Percentage of Predicted Normal at 4 weeks. Started Apr 2009; status: completed.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT00885365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00885365.